Zedira Presents Clinical Candidate for Celiac Disease Therapy
Blocking tissue transglutaminase is a promising therapeutic option in celiac disease. Zedira developed rationally designed peptidomimetic blockers bearing a michael acceptor pharmacophore. The safety profile and selectivity over other transglutaminase isoenzymes make ZED-101 an optimal candidate for subsequent clinical development.
Zedira considers either out-licensing ZED-101 to a pharmaceutical company or further conducting preclinical and clinical trials backed by investors.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.